1.20
-0.03(-2.44%)
Currency In USD
Address
919 East Hillsdale Boulevard
Foster City, CA 94404
United States of America
Phone
650 473 7700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
229
First IPO Date
July 31, 1996
| Name | Title | Pay | Year Born |
| Ms. Dawn Carter Bir | Interim President & Chief Executive Officer and Director | 64,158 | 1971 |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research & Development | 304,098 | 1967 |
| Mr. Scott Samuels | Executive Vice President, Chief Legal Officer & Secretary | 485,317 | N/A |
| Mr. James Ziegler M.B.A. | Executive Vice President & Chief Commercial Officer | 618,670 | 1966 |
| Ms. Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 846,376 | 1967 |
| Dr. Andrew J. Grethlein Ph.D. | Executive Vice President & Chief Operating Officer | 977,476 | 1964 |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Ms. Shannon T. Odam | Executive Vice President & Chief People Officer | 0 | 1975 |
| Dr. Faye Feller M.D. | Executive Vice President & Chief Medical Officer | 0 | 1983 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.